Procurement teams sourcing clinical bioimpedance and body-composition analyzers for Canadian or Australian markets face a structurally similar but procedurally distinct regulatory landscape. Both Health Canada and Australia's Therapeutic Goods Administration (TGA) operate risk-based classification systems; both require pre-market review for clinical-grade devices; both accept ISO 13485 as the quality management baseline. The differences lie in the submission mechanics, the database structures, and the degree to which prior foreign market approvals can be leveraged. This guide maps those differences for procurement professionals.

How does Health Canada MDALL differ from TGA ARTG?

The Medical Devices Active Licence Listing (MDALL) is Health Canada's public database of currently licensed medical devices in Canada. A device appearing on MDALL holds a Medical Device Licence (MDL), which is the legal prerequisite for sale or import into Canada. The Australian Register of Therapeutic Goods (ARTG) is the equivalent database maintained by TGA, listing devices that have been included in the register following conformity assessment and may be legally supplied in Australia.

The structural difference matters for sourcing: MDALL is a licence issued to the manufacturer or importer, tied to a specific device model and intended use. ARTG inclusion is tied to a sponsor — the entity (often the Australian distributor or importer) responsible for the device in Australia. This means a single manufacturer may have multiple sponsors holding separate ARTG entries for the same product, and a change in the Australian distributor can require a new or transferred ARTG entry. Under MDALL, the MDL is typically held by the manufacturer or a Canadian importer, and distributor changes do not automatically require a new MDL, though the regulatory records must be updated.

Classification comparison for bioimpedance devices

Both systems use risk-based classification, but the class designations use different numbering conventions:

Dimension	Health Canada	TGA (Australia)
Typical class for clinical BIA analyzer	Class II	Class IIa
Pre-market review required?	Yes — MDL application	Yes — ARTG inclusion application
Primary legislation	Medical Devices Regulations (SOR/98-282)	Therapeutic Goods Act 1989 + Medical Devices Regulations 2002
QMS requirement	Adequate QMS (ISO 13485 accepted)	ISO 13485 required (mandatory conformity)
Electrical safety standard	IEC 60601-1 / CSA C22.2 No. 60601-1	IEC 60601-1 / AS/NZS IEC 60601-1
Post-market surveillance	Mandatory incident reporting to Health Canada	Mandatory adverse event reporting to TGA
Public verification database	MDALL (Health Canada website)	ARTG Public Summary (TGA website)

Can prior regulatory approval in one jurisdiction accelerate the other?

This is the question most relevant to procurement teams working with manufacturers who hold approvals in multiple markets. The answer is: sometimes, partially, and only if the submission is structured correctly.

Health Canada operates a Comparable Foreign Regulatory Authority (CFRA) framework that allows applicants to reference approvals from designated comparable regulators — including the US FDA, the EU under CE marking, and TGA — to support their Health Canada submission. The TGA ARTG listing can be cited as comparable regulatory evidence, but it does not substitute for a Health Canada MDL. The manufacturer or Canadian importer must still file a Class II application, provide a Declaration of Conformity, and meet Health Canada's specific requirements. The CFRA pathway can reduce the burden of technical documentation if the foreign approval was based on a similar technical file, but it does not eliminate the review requirement.

TGA similarly accepts evidence from international regulators but requires that the device be assessed against Australian standards and that the ARTG sponsor assume full regulatory responsibility in Australia. CE marking under EU MDR is considered more directly comparable to TGA requirements than Health Canada's framework, owing to the shared conformity assessment structure. For body-composition devices being brought to both Canada and Australia simultaneously, the most efficient pathway is to develop the core technical file to EU MDR standards and then adapt for each jurisdiction's specific requirements, rather than building separate files for each.

What the procurement team actually needs to verify

For procurement of body-composition analyzers, the practical verification checklist differs between the two markets:

For Canada: search MDALL for the exact device model and confirm the licence is active (not expired or suspended). Confirm the MDL covers the intended clinical use — some licences are scoped to specific indications or user populations. Verify that the Canadian importer or the manufacturer holds the MDL (the entity on the MDL is legally responsible for the device in Canada). For clinical device sourcing, also confirm the local post-market surveillance arrangements.

For Australia: search the ARTG Public Summary for the device and sponsor. Confirm the ARTG entry covers the specific model and configuration being purchased — ARTG entries can cover device families with multiple configurations, and procurement teams should verify the exact model is within scope. Confirm the sponsor is the entity supplying the device into Australia. Review the post-market surveillance obligations and confirm the sponsor has arrangements to report adverse events to TGA.

Mutual recognition and bilateral agreements

Canada and Australia are both members of the International Medical Device Regulators Forum (IMDRF) and participate in harmonisation work through that body. However, they do not have a bilateral mutual recognition agreement for medical devices that allows automatic cross-recognition of device approvals. The IMDRF convergence work does mean that technical documentation requirements are increasingly aligned at the framework level — but each jurisdiction retains its own licensing or registration process.

For manufacturers and procurement teams planning multi-market launches, the practical implication is that regulatory timelines must be planned in parallel rather than in sequence. A device that has completed TGA ARTG inclusion is not available in Canada until a Canadian MDL is also obtained. See our sourcing process for how we structure multi-market regulatory timelines for clinical device procurement.

Key differences in post-market obligations

Both regulators require post-market surveillance and adverse event reporting, but the specific thresholds and timelines differ. Health Canada requires reporting of serious incidents and field safety corrective actions under the Medical Devices Regulations. TGA requires reporting of adverse events under the Therapeutic Goods Act, with specific timeframes based on event severity. Procurement contracts for aged-care fleets should include obligations on the supplier to notify the procuring organisation of any field safety corrective actions or regulatory communications from either Health Canada or TGA, depending on the market.

加拿大医疗器械主动许可清单（MDALL）是Health Canada的公开数据库，列明在加拿大持有医疗器械许可证（MDL）的设备。澳大利亚治疗产品登记册（ARTG）是TGA维护的等效数据库。两个数据库均采用基于风险的分类体系，临床BIA分析仪在加拿大通常被分类为II类，在澳大利亚为IIa类。

两个体系的核心差异：MDALL许可证通常颁给制造商或加拿大进口商；ARTG登记则与澳大利亚保荐人（通常为当地分销商）绑定。TGA的ARTG登记可作为Health Canada提交中的比较监管证据，但不能替代MDL。最高效的多市场路径是以欧盟MDR标准构建核心技术文档，再分别针对各司法管辖区调整。

采购核查重点——加拿大：在MDALL核实具体型号的有效许可证及适用范围。澳大利亚：在ARTG公开摘要核实设备及保荐人，确认具体型号及配置在登记范围内。两地均须确认售后监测安排。详见临床设备采购及采购流程。

加拿大醫療器械主動許可清單（MDALL）是Health Canada的公開數據庫，列明在加拿大持有醫療器械許可證（MDL）的設備。澳大利亞治療產品登記冊（ARTG）是TGA維護的等效數據庫。兩個數據庫均採用基於風險的分類體系，臨床BIA分析儀在加拿大通常被分類為II類，在澳大利亞為IIa類。

兩個體系的核心差異：MDALL許可證通常頒給製造商或加拿大進口商；ARTG登記則與澳大利亞保薦人（通常為當地分銷商）綁定。TGA的ARTG登記可作為Health Canada提交中的比較監管證據，但不能替代MDL。最高效的多市場路徑是以歐盟MDR標準構建核心技術文檔，再分別針對各司法管轄區調整。

採購核查重點——加拿大：在MDALL核實具體型號的有效許可證及適用範圍。澳大利亞：在ARTG公開摘要核實設備及保薦人，確認具體型號及配置在登記範圍內。兩地均須確認售後監測安排。詳見臨床設備採購及採購流程。